RBC Capital analyst Shagun Singh upgraded Zimmer Biomet to Outperform from Sector Perform with a price target of $141, up from $125. For 2023, The analyst favors medical supply and device stocks with exposure to procedures less likely to be deferred, new product cycles and the ability to win market share. Singh upgraded Zimmer on easing currency headwinds, upside from the launch of cement-less products, and potential upside from its backlog.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $130 from $120 at Piper Sandler
- Zimmer Biomet to Acquire Embody, Inc.
- Zimmer Biomet to acquire Embody for $155M at closing
- Zimmer Biomet upgraded to Outperform from Market Perform at Raymond James
- Zimmer Biomet downgraded to In Line at Evercore ISI with FY23 outlook priced in
